Lessee, Operating Lease, Liability, to be Paid, Year One of CRISPR Therapeutics AG from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
Summary
CRISPR Therapeutics AG quarterly Lessee, Operating Lease, Liability, to be Paid, Year One in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • CRISPR Therapeutics AG Lessee, Operating Lease, Liability, to be Paid, Year One for the quarter ending 31 Dec 2025 was $29,684,000, a 0.91% increase year-over-year.
Source SEC data
View on sec.gov
Lessee, Operating Lease, Liability, to be Paid, Year One, Quarterly (USD)
Lessee, Operating Lease, Liability, to be Paid, Year One, YoY Quarterly Change (%)

CRISPR Therapeutics AG Quarterly Lessee, Operating Lease, Liability, to be Paid, Year One (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $29,684,000 +$268,000 +0.91% 31 Dec 2025 10-K 12 Feb 2026 2025 FY
Q4 2024 $29,416,000 +$713,000 +2.5% 31 Dec 2024 10-K 11 Feb 2025 2024 FY
Q4 2023 $28,703,000 -$567,000 -1.9% 31 Dec 2023 10-K 21 Feb 2024 2023 FY
Q4 2022 $29,270,000 +$11,014,000 +60% 31 Dec 2022 10-K 21 Feb 2023 2022 FY
Q4 2021 $18,256,000 +$1,236,000 +7.3% 31 Dec 2021 10-K 15 Feb 2022 2021 FY
Q4 2020 $17,020,000 +$3,057,000 +22% 31 Dec 2020 10-K 16 Feb 2021 2020 FY
Q4 2019 $13,963,000 31 Dec 2019 10-K 12 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.